Keyphrases
Head-and-neck Cancer
100%
Time-to-event Data
82%
Joint Modeling
57%
Cisplatin
53%
India
46%
Chemoradiation
42%
COVID-19
39%
Overall Survival
38%
Hazard Ratio
36%
Metronomic Chemotherapy
35%
Adjuvant Chemotherapy
34%
Feature Selection
30%
Randomized Phase III Trial
27%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
27%
Meta-analysis
27%
Disease Progression
25%
COVID-19 Pandemic
25%
Confidence Interval
24%
Checkpoint Inhibitors
24%
Parameter Estimation
24%
Bayesian Approach
23%
Frailty Effects
23%
Nimotuzumab
23%
Risk Detection
23%
Modified Risk
23%
Biomarker Studies
23%
UK Biobank
23%
Randomized Trial
23%
Missingness
23%
Walking Pace
23%
Detection Method
23%
Oncology
23%
Frailty
23%
Multiple Imputation
23%
Missing Data
23%
Oral Cancer
23%
Docetaxel
23%
Survival Outcomes
23%
Feature Selection Methods
23%
Systematic Meta-analysis
23%
Competing Risks
21%
Accelerated Failure Time Model
21%
High-dimensional Data
21%
Survival Analysis
20%
Generalized Estimating Equations
19%
Cancer Patients
19%
Low-middle Income Countries
19%
Cardiovascular Disease
18%
Censored Data
17%
Survival Model
17%
Medicine and Dentistry
Head and Neck Cancer
54%
Arm
45%
Malignant Neoplasm
37%
Overall Survival
35%
Cardiovascular Disease
34%
Cisplatin
34%
COVID-19
34%
Hazard Ratio
23%
UK Biobank
23%
Low Drug Dose
23%
Immunotherapy
23%
Nimotuzumab
23%
Nivolumab
23%
Meta-Analysis
23%
Systematic Review
23%
Diseases
19%
Low and Middle Income Countries
18%
Health Care Cost
17%
Mortality Rate
16%
Alcohol Consumption
15%
Oral Cancer
15%
Chemoradiotherapy
14%
Re-Irradiation
12%
Head and Neck Squamous Cell Carcinoma
11%
Recurrent Disease
11%
Adjuvant Radiotherapy
11%
Time Series Analysis
11%
Prospective Study
11%
High-Density Lipoprotein
11%
Screening Test
11%
Cardiovascular System Cancer
11%
Prospective Cohort Study
11%
Muscle Invasive Bladder Cancer
11%
Case Fatality Rate
11%
Cystectomy
11%
Non Communicable Disease
11%
Prevalence
11%
Tobacco Use
11%
Cancer Incidence
11%
Cancer Risk
11%
Ganglioglioma
11%
Adjuvant Chemotherapy
11%
Head and Neck Carcinoma
11%
Mebendazole
11%
Cell Cycle M Phase
11%
Oropharynx Carcinoma
11%
Quality of Life
11%
Pandemic
11%
Adverse Event
8%
Intensive Care Unit
8%